In one preclinical study, CAFs induced cisplatin resistance in bladder cancer cells through exosomal miR-146a-5p [122], which activated the STAT3 and mTOR signaling pathways by targeting ARID1A and PRKAA2 [122]. The gene discussed is MTOR; the disease is urinary bladder cancer.